Axtria has been recognised as the leader in Frost & Sullivan's inaugural Pharmaceutical Commercialization Solutions and Services Industry Radar Report.
Key Report Highlights Include:
Innovation Excellence - Axtria's innovative leveraging of data science and cloud-based analytics platforms empowers life sciences companies to enhance patient outcomes. Its suite of platforms-including Axtria DataMAxTM, Axtria InsightsMAxTM, Axtria SalesIQTM, Axtria CustomerIQTM, and Axtria MarketingIQTM-streamlines data utilization, enabling pharmaceutical companies to optimize sales, marketing, and end-to-end commercial operations.
Sustainable Growth Leadership - With operations in more than 70 countries and a team of over 3,800 professionals, Axtria achieves annual double-digit growth. Recent expansions include:
- New Global Innovation Centers: Recently, Axtria expanded its headquarters in New Jersey and inaugurated its 10th center in Hyderabad, India.
- Expanding Workforce: Axtria plans to grow its employee base by over 1,000, focusing on roles in data science, software development, and data engineering.
- Global Footprint: Recent expansions underscore Axtria's commitment to scaling operations and supporting global healthcare innovation.
Recognition and Strategic Initiatives - Axtria's focus on thought leadership and knowledge sharing continues to strengthen its brand recall. In June 2024, the company hosted over 350 senior leaders from 65 top pharmaceutical organizations at Axtria Ignite, where they discussed key industry topics such as patient engagement, generative AI, and omnichannel orchestration. This strategic focus positions Axtria as a pioneer in transforming pharmaceutical commercialization operations through technology.
Get complimentary access to the full “Pharmaceutical Commercialization Solutions and Services Industry Radar Report.”
Contact us at connect@axtria.com with any questions.
Recommended insights
White Paper
Reports
Article